Evidence map›Paper›PMID 39799339›Full record

ReviewActa neuropathologica communications2025

Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.

Niclas Skarne, Rochelle C J D'Souza, Helen M Palethorpe, Kylah A Bradbrook, Guillermo A Gomez, Bryan W Day

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Niclas SkarneSid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia. Niclas.Skarne@qimrberghofer.edu.au.
Rochelle C J D'SouzaSid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Helen M PalethorpeCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.
Kylah A BradbrookSid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Guillermo A GomezCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, 5000, Australia.
Bryan W DaySid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia. Bryan.Day@qimrberghofer.edu.au.

Funding

NHMRC 2021/GNT2013180 and 2023/GNT2030541the Medical Research Future Fund (MRFF) Australian Brain Cancer Infrastructure Grant 2023943the Medical Research Future Fund (MRFF) Rapid Applied Research Translation Program, Centre for Personalised Analysis of Cancers (CPAC) GA59729
6 · The paper itself

Abstract

Glioblastoma (GBM) is a highly aggressive adult brain cancer, characterised by poor prognosis and a dismal five-year survival rate. Despite significant knowledge gains in tumour biology, meaningful advances in patient survival remain elusive. The field of neuro-oncology faces many disease obstacles, one being the paucity of faithful models to advance preclinical research and guide personalised medicine approaches. Recent technological developments have permitted the maintenance, expansion and cryopreservation of GBM explant organoid (GBO) tissue. GBOs represent a translational leap forward and are currently the state-of-the-art in 3D in vitro culture system, retaining brain cancer heterogeneity, and transiently maintaining the immune infiltrate and tumour microenvironment (TME). Here, we provide a review of existing brain cancer organoid technologies, in vivo xenograft approaches, evaluate in-detail the key advantages and limitations of this rapidly emerging technology, and consider solutions to overcome these difficulties. GBOs currently hold significant promise, with the potential to emerge as the key translational tool to synergise and enhance next-generation omics efforts and guide personalised medicine approaches for brain cancer patients into the future.

Indexed as

Brain NeoplasmsGlioblastomaOrganoidsPrecision MedicineAnimalsHumansTumor MicroenvironmentBrain cancerExplantsGlioblastomaHeterogeneityOrganoidsPatient-derivedPersonalised medicine

Identifiers

PMID39799339
PMCPMC11724554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.